Cytovation
Clinical stage immune-oncology company focused on the development of its targeted tumor membrane immunotherapy
Cytovation has raised €25M across 2 funding rounds from 2 investors, most recently a Series A round in Jun 2023. Based in Bergen, Norway; active in Healthtech. Data as of 28 Oct 2026.
Bergen, Norwaywww.cytovation.com ↗
Total raised
€25M
€25,185,597
Funding rounds
2
Investors
2
distinct backers
Active since
2022-01
latest 2023-06
Funding by year
EUR raised per yearCytovation — funding by year — interactive chart.
Data table
| Cytovation — funding by year | |
|---|---|
| 2022 | €18M |
| 2023 | €7.4M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Down/flat last round
Exit likelihood9
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-06-12 | Series A | €7.4M | Canica,Sandwater | View deal → |
| 2022-01-25 | Series A | €18M | Canica,Sandwater | View deal → |
Related news
- Cytovation Raises $20M in Series A Financingfinsmes.com · 2022-01
- arcticstartup.com
Similar companies
same sector or country- Visma€3.0BNorway · Software
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Adevinta€1.9BNorway · Marketing
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
Global coverage: FundingData